RxDoctor Payments Data

Paul Dimuzio, MD

Vascular Surgery · Philadelphia, PANPI 1942220629

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (47.4%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 22.7%. Reporting peaked in 2019 at $7,518 and has fallen 91.6% since, to $628 in 2025.

$15,026in general payments, 2019–2025

Across 178 payments — averaging $84.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Silk Road Medical, Inc.$3K
  • Cook Incorporated$3K
  • Cook Medical LLC$3K
  • W. L. Gore & Associates, Inc.$2K
  • Inari Medical, Inc.$2K
  • Medtronic$368
  • plus $2K from 17 others
$162,213in research payments, 2019–2025

Across 15 payments — averaging $10,814 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • KCI USA, Inc.$120K
  • Solventum Corporation$31K
  • Silk Road Medical, Inc.$7K
  • Endologix LLC$4K

What the payments were for

  • Consulting fees$1,2008%
  • Speaking & faculty fees$3,00020%
  • Travel & lodging$3,67024%
  • Food & beverage$7,12147%
  • Education$350%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,026 in reported general payments places this provider in the 80th percentile of 236 vascular surgery providers in Pennsylvania.

See all vascular surgery providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$146,288
Medicare patients
449
Services billed
738

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cilostazol36$908
ClopidogrelClopidogrel Bisulfate55$906

Paid to pharmacies, not to this prescriber.

Other vascular surgery in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →